Each tablet contains Trimetazidine Hydrochloride BP 35 mg.
Trimetazidine Hydrochloride has been proven to exert antianginal properties due to its specific metabolic mechanism of action. Trimetazidine Hydrochloride reduces the metabolic damage caused during ischemia, by acting on a critical step in cardiac metabolism: fatty acid β-oxidation. This is made possible by selectively inhibiting an enzyme of fatty acid β-oxidation: the long-chain 3-ketoacyl CoA thiolase (3-KAT). This inhibition results in a reduction in fatty acid oxidation & stimulation of glucose oxidation.
Thus, the coupling of glycolysis with glucose oxidation is improved, and ATP production is further increased, while the harmful consequences of acidosis and of Ca2+ overload are limited.
Trimetazidine Dihydrochloride is indicated for long-term treatment of angina pectoris.
Trimetazidine dihydrochloride 35 mg twice daily or 20 mg three times daily during meals. After three months of consumption, should go again to the doctor.
Hypersensitivity to Trimetazidine Hydrochloride should not be used.
Trimetazidine Dihydrochloride is a well-tolerated drug. But there may be some immediate problems.
No drug interactions. No interaction with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic drugs, or digitalis in particular.
Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, the prescription should be avoided during pregnancy.
Breastfeeding: In the absence of data, breastfeeding is not recommended during treatment.
Protect from light and moisture—store below 30° C. Keep the medicine out of reach of children.